Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Acoramidis reduces days lost to death and/or cardiovascular-related hospitalization, preserving time alive outside the hospital in participants with ATTR-CM: results from ATTRibute-CM
To evaluate the effect of acoramidis on reducing days lost to death and/or cardiovascular-related hospitalization (DLDCVH) versus placebo in participants with transthyretin amyloid cardiomyopathy (ATTR-CM) over 30 and 36 months.
In participants with ATTR-CM, acoramidis significantly reduced DLDCVH versus placebo.
Acoramidis preserved more than 1 month (38 days) of time alive outside the hospital over 30 months versus placebo, with this benefit extending to 65 days over 36 months using OLE-based data and to 94 days with placebo-extrapolated estimates, reflecting progressive divergence in outcomes over time.
A greater proportion of acoramidis-treated participants experienced zero DLDCVH than placebo recipients, consistent with a clinically meaningful treatment benefit with acoramidis.
These findings suggest that acoramidis may reduce healthcare resource utilization by decreasing hospitalization burden while helping patients spend more time alive at home, an important consideration for healthcare decision-making.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
